Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)

Stock Information for Marizyme Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marizyme Inc

Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
Marizyme CEO Delivers Business Update
InvestmentPitch Media Video Features Marizyme's CEO David Barthel Discussing Receipt of FDA Clearance for its Flagship DuraGraft Medical Device
The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft(TM)
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
Marizyme CEO Delivers Business Update
Statera Biopharma Announces Changes to Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.